Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NLTX NASDAQ:NVCT NASDAQ:TARA NYSEAMERICAN:XTNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNLTXNeoleukin Therapeutics$29.00+3.5%$26.58$2.03▼$14.36$272.54M1.1150,104 shs127,106 shsNVCTNuvectis Pharma$10.71+1.9%$9.54$5.55▼$13.34$278.78M-0.0793,333 shs69,105 shsTARAProtara Therapeutics$3.90+6.8%$4.90$2.77▼$7.82$205.15M1.45818,693 shs524,536 shsXTNTXtant Medical$0.44+2.1%$0.49$0.43▼$0.95$60.42M-0.16135,757 shs57,097 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNLTXNeoleukin Therapeutics-2.78%+6.83%-9.32%+25.61%+29.80%NVCTNuvectis Pharma+1.94%+8.69%-3.58%+16.39%+19.03%TARAProtara Therapeutics-3.44%-17.23%-29.13%-30.61%+10.94%XTNTXtant Medical-2.27%-6.54%-14.75%-30.76%-36.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNLTXNeoleukin Therapeutics$29.00+3.5%$26.58$2.03▼$14.36$272.54M1.1150,104 shs127,106 shsNVCTNuvectis Pharma$10.71+1.9%$9.54$5.55▼$13.34$278.78M-0.0793,333 shs69,105 shsTARAProtara Therapeutics$3.90+6.8%$4.90$2.77▼$7.82$205.15M1.45818,693 shs524,536 shsXTNTXtant Medical$0.44+2.1%$0.49$0.43▼$0.95$60.42M-0.16135,757 shs57,097 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNLTXNeoleukin Therapeutics-2.78%+6.83%-9.32%+25.61%+29.80%NVCTNuvectis Pharma+1.94%+8.69%-3.58%+16.39%+19.03%TARAProtara Therapeutics-3.44%-17.23%-29.13%-30.61%+10.94%XTNTXtant Medical-2.27%-6.54%-14.75%-30.76%-36.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNLTXNeoleukin Therapeutics 0.00N/AN/AN/ANVCTNuvectis Pharma 2.00Hold$13.0021.38% UpsideTARAProtara Therapeutics 2.75Moderate Buy$26.25573.08% UpsideXTNTXtant Medical 3.00Buy$1.00127.27% UpsideCurrent Analyst Ratings BreakdownLatest XTNT, NVCT, NLTX, and TARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026NVCTNuvectis Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $13.006/5/2026NVCTNuvectis Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/20/2026TARAProtara Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$25.00 ➝ $28.005/20/2026TARAProtara Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/20/2026TARAProtara Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026TARAProtara Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/14/2026TARAProtara Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$27.00 ➝ $26.005/13/2026XTNTXtant Medical BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.004/29/2026TARAProtara Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $27.004/21/2026TARAProtara Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/31/2026XTNTXtant Medical BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1.50 ➝ $1.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.72 per shareN/ATARAProtara TherapeuticsN/AN/AN/AN/A$3.80 per shareN/AXTNTXtant Medical$133.93M0.46$0.07 per share5.92$0.36 per share1.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNLTXNeoleukin Therapeutics-$57.56M-$3.11N/AN/AN/AN/A-37.22%-30.91%N/ANVCTNuvectis Pharma-$26.44M-$1.31N/AN/AN/AN/A-161.00%-98.88%8/4/2026 (Estimated)TARAProtara Therapeutics-$57.44M-$1.34N/AN/AN/AN/A-38.70%-36.02%7/30/2026 (Estimated)XTNTXtant Medical$4.97M-$0.1344.04N/AN/A1.50%3.68%1.91%7/30/2026 (Estimated)Latest XTNT, NVCT, NLTX, and TARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026TARAProtara Therapeutics-$0.36-$0.31+$0.05-$0.31N/AN/A5/13/2026Q1 2026XTNTXtant Medical-$0.0150-$0.02-$0.0050-$0.02$20.16 million$20.88 million5/5/2026Q1 2026NVCTNuvectis Pharma-$0.30-$0.26+$0.04-$0.26N/AN/A3/31/2026Q4 2025XTNTXtant Medical-$0.0049$0.0263+$0.0312N/A$30.75 million$32.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/AXTNTXtant MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNLTXNeoleukin TherapeuticsN/A15.3315.33NVCTNuvectis PharmaN/A2.272.27TARAProtara TherapeuticsN/A15.6915.69XTNTXtant Medical0.173.341.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNLTXNeoleukin Therapeutics52.37%NVCTNuvectis Pharma96.77%TARAProtara Therapeutics38.13%XTNTXtant Medical69.33%Insider OwnershipCompanyInsider OwnershipNLTXNeoleukin Therapeutics1.58%NVCTNuvectis Pharma28.55%TARAProtara Therapeutics7.60%XTNTXtant Medical10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataNVCTNuvectis Pharma826.53 million18.95 millionNot OptionableTARAProtara Therapeutics3056.20 million51.93 millionOptionableXTNTXtant Medical120140.26 million125.68 millionNot OptionableXTNT, NVCT, NLTX, and TARA HeadlinesRecent News About These CompaniesXtant Medical Holdings Inc (XTNT) Q1 2026 Earnings Call Highlights: Navigating Challenges and ...May 15, 2026 | finance.yahoo.comXtant Medical Q1 Earnings Call HighlightsMay 15, 2026 | marketbeat.comXtant Medical Holdings, Inc.May 15, 2026 | edition.cnn.comXtant Medical Holdings, Inc. Q1 2026 Earnings Call SummaryMay 15, 2026 | finance.yahoo.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comXtant Medical Hldgs Q1 2026 Earnings Call TranscriptMay 13, 2026 | finance.yahoo.comXtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comXtant Medical Holdings, Inc.: Xtant Medical Reports First Quarter 2026 Financial ResultsMay 13, 2026 | finanznachrichten.deXtant Medical Reports First Quarter 2026 Financial ResultsMay 13, 2026 | prnewswire.comXtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026May 7, 2026 | prnewswire.comXtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ ShapedMay 6, 2026 | prnewswire.comXtant Medical Holdings (XTNT) price target increased by 12.12% to 1.26April 28, 2026 | msn.comXtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows ProductApril 13, 2026 | prnewswire.comXtant Medical Holdings (XTNT) price target decreased by 18.52% to 1.12April 10, 2026 | msn.comXtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" MemorialApril 9, 2026 | prnewswire.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2025 Earnings Call TranscriptApril 1, 2026 | insidermonkey.comXtant outlines $95M-$99M 2026 revenue outlook as Companion Spine divestiture and Q-code license revenue roll offMarch 31, 2026 | msn.comXtant Medical shares drop nearly 5% as weak 2026 outlook overshadows Q4 beatMarch 31, 2026 | msn.comXtant Medical Holdings Inc (XTNT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...March 31, 2026 | finance.yahoo.comXtant Medical Holdings, Inc. (XTNT) Q4 2025 Earnings Call TranscriptMarch 31, 2026 | seekingalpha.comXtant Medical Reports Fourth Quarter and Full-Year 2025 Financial ResultsMarch 31, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTNT, NVCT, NLTX, and TARA Company DescriptionsNeoleukin Therapeutics NASDAQ:NLTX$29.00 +0.99 (+3.53%) As of 06/11/2026Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Nuvectis Pharma NASDAQ:NVCT$10.71 +0.20 (+1.90%) Closing price 04:00 PM EasternExtended Trading$10.73 +0.02 (+0.19%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Protara Therapeutics NASDAQ:TARA$3.90 +0.25 (+6.85%) Closing price 04:00 PM EasternExtended Trading$4.11 +0.21 (+5.46%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.Xtant Medical NYSEAMERICAN:XTNT$0.44 +0.01 (+2.14%) As of 04:10 PM EasternXtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
